Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zeng, Jieming ^a   Wu, Chunxiao ^a   Wang, Shu ^a,b  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; MELAN A; TUMOR ANTIGEN;

CD8+ T LYMPHOCYTE; CELL LINE; CYTOLOGY; DENDRITIC CELL; DNA RESPONSIVE ELEMENT; GENE VECTOR; GENETICS; HUMAN; IMMUNOCOMPETENCE; IMMUNOLOGY; METABOLISM; NEOPLASMS; PLURIPOTENT STEM CELL; REPORTER GENE;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; EPITOPES; GENES, REPORTER; GENETIC VECTORS; HUMANS; IMMUNOCOMPETENCE; MART-1 ANTIGEN; NEOPLASMS; PLURIPOTENT STEM CELLS; RESPONSE ELEMENTS;

EID: 84944226454     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15262     Document Type: Article

References (29)

1. Galluzzi, L. et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 1, 1111-1134 (2012).
2. Vacchelli, E. et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2, e25771 (2013).
3. Butterfield, L. H. Dendritic cells in cancer immunotherapy clinical trials: are we making progress Front Immunol 4, 454 (2013).
4. Gilboa, E. DC-based cancer vaccines. J Clin Invest 117, 1195-1203 (2007).
5. Nicolette, C. A. et al. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 25 Suppl 2, B47-60 (2007).
6. Wimmers, F., Schreibelt, G., Skold, A. E., Figdor, C. G., De Vries, I. J. Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Front Immunol 5, 165 (2014).
7. DeFrancesco, L. Landmark approval for Dendreon's cancer vaccine. Nat Biotechnol 28, 531-532 (2010).
8. Senju, S. et al. Immunotherapy with pluripotent stem cell-derived dendritic cells. Semin Immunopathol 33, 603-612 (2011).
9. Zeng, J., Shahbazi, M., Wu, C., Toh, H. C., Wang, S. Enhancing immunostimulatory function of human embryonic stem cellderived dendritic cells by CD1d overexpression. J Immunol 188, 4297-4304 (2012).
10. Zeng, J., Wang, S. Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response. Stem Cells Transl Med 3, 69-80 (2014).
11. Nierkens, S., Janssen, E. M. Harnessing dendritic cells for tumor antigen presentation. Cancers (Basel) 3, 2195-2213 (2011).
12. Morel, S. et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12, 107-117 (2000).
13. Slukvin, I. I., Vodyanik, M. A., Thomson, J. A., Gumenyuk, M. E., Choi, K. D. Directed differentiation of human embryonic stem cells into functional dendritic cells through the myeloid pathway. J Immunol 176, 2924-2932 (2006).
14. Chen, D. S., Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10 (2013).
15. Haruta, M. et al. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigenpresenting cells. Gene Ther 20, 504-513 (2013).
16. Senju, S. et al. Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function. Stem Cells 25, 2720-2729 (2007).
17. Su, Z., Frye, C., Bae, K. M., Kelley, V., Vieweg, J. Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions. Clin Cancer Res 14, 6207-6217 (2008).
18. Tseng, S. Y. et al. Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. Regen Med 4, 513-526 (2009).
19. Robson, N. C., Hoves, S., Maraskovsky, E., Schnurr, M. Presentation of tumour antigens by dendritic cells and challenges faced. Curr Opin Immunol 22, 137-144 (2010).
20. Wilson, N. S., Villadangos, J. A. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 86, 241-305 (2005).
21. Smits, E. L., Anguille, S., Cools, N., Berneman, Z. N., Van Tendeloo, V. F. Dendritic cell-based cancer gene therapy. Hum Gene Ther 20, 1106-1118 (2009).
22. Breckpot, K., Heirman, C., Neyns, B., Thielemans, K. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 6, 1175-1188 (2004).
23. Kreiter, S., Diken, M., Selmi, A., Tureci, O., Sahin, U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 23, 399-406 (2011).
24. Fontes, A., Lakshmipathy, U. Advances in genetic modification of pluripotent stem cells. Biotechnol Adv 31, 994-1001 (2013).
25. Kennedy, R., Celis, E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunological reviews 222, 129-144 (2008).
26. Liechtenstein, T., Perez-Janices, N., Escors, D. Lentiviral vectors for cancer immunotherapy and clinical applications. Cancers (Basel) 5, 815-837 (2013).
27. Gaj, T., Gersbach, C. A., Barbas, C. F., 3rd ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in biotechnology 31, 397-405 (2013).
28. Sadelain, M., Papapetrou, E. P., Bushman, F. D. Safe harbours for the integration of new DNA in the human genome. Nature reviews. Cancer 12, 51-58 (2012).
29. Stanke, J. et al. A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function. J Immunol Methods 360, 56-65 (2010).